Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: Results from the AT.LANTUS trial

Diabetes, Obesity and Metabolism

Volumn 10, Issue 5, 2008, Pages 387-399

  Davies, Melanie ^a   Lavalle Gonzalez F ^b   Storms, F ^c   Gomis, R ^d  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c Mesos Diabetes Centrum   (Netherlands)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Basal insulin analogues; Insulin glargine; Oral antidiabetic agents; Titration; Treatment algorithms; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 42149129416     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00873.x     Document Type: Article

References (44)

1. Davidson JA. Treatment of the patient with diabetes: Importance of maintaining target HbA(1c) levels. Curr Med Res Opin 2004; 20: 1919-1927.
2. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006; 29: S4-S42.
3. Department of Health. National Service Framework for Diabetes: Standards. London: Department of Health, 2002.
4. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.
5. Eliasson B, Cederholm J, Nilsson P, Gudbjornsdottir S. The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med 2005; 22: 1420-1426.
6. Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004; 28 (Suppl. 2): S14-S22.
7. LaMonte MJ, Blair SN, Church TS. Physical activity and diabetes prevention. J Appl Physiol 2005; 99: 1205-1213.
8. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-228.
9. Koenigsberg MR, Bartlett D, Cramer JS. Facilitating treatment adherence with lifestyle changes in diabetes. Am Fam Physician 2004; 69: 309-316.
10. Steppel JH, Horton ES. Beta-cell failure in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep 2004; 4: 169-175.
11. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197-209.
12. Monnier L, Colette C, Rabasa-Lhoret R et al. Morning hyperglycemic excursions: A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002; 25: 737-741.
13. Turner R, Cull C, Frighi V, Holmann R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
14. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 2002; 8: 271-275.
15. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26: S18-S24.
16. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28: 2673-2679.
17. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
18. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabet Med 2003; 20: 545-551.
19. Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type 2 diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res 1996; 28: 451-455.
20. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.
21. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006; 49: 442-451.
22. Fritsche A, Schweitzer M, Haring H-U; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959.
23. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: Subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci 2004; 328: 274-280.
24. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
25. Riddle M, Rosenstock J, Gerich J;
26. Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
27. Lechleitner M, Roden M, Haehling E, Mueller M. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wien Klin Wochenschr 2005; 117: 593-598.
28. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
29. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
30. Marshall SM, Barth JH. Standardization of HbA1c measurements - a consensus statement. Diabet Med 2000; 17: 5-6.
31. Marshall SM, Home PD, Manley SE, Barth JH, John WG. Standardization of glycated haemoglobin. Diabet Med 2002; 19: 429.
32. Fulcher GR, Storms F, Shutler S, Leperlier C, Gomis R, Davies M. Initiation of insulin glargine in patients with type 2 diabetes sub-optimally controlled on once-or twice-daily NPH insulin: Results from the AT.LANTUS Trial. European Association for the Study of Diabetes Annual Congress. Diabetologia (Munich) 2004; 47 (Suppl. 1): 272 (Abstract 750).
33. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Initiation of insulin glargine in type 2 patients with suboptimal glycaemic control on twice-daily premix insulin: Results from the AT.LANTUS Trial. European Association for the Study of Diabetes. Diabetologia (Munich) 2004; 47 (Suppl. 1): 56 (Abstract 146).
34. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002; 45: 937-948.
35. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
36. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
37. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647-1653.
38. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
39. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955.
40. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189-196.
41. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
42. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-2044.
43. Snoek FJ, Dain M-P, Polonsky WH. Perceptions of seriousness and management of diabetes. Findings from the SHARED study (Survey comparing Healthcare professionals and patients to Assess REal perceptions of Diabetes issues). Diabetologia 2006; 49: 551 (Abstract 0905).
44. Yki-Jarvinen H, Juurinen L, Alvarsson M et al. Initiate insulin by aggressive titration and education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-1369.